BiomX
Customized phage therapies to eradicate harmful bacteria in chronic diseases.
Launch date
Employees
Market cap
$17.8m
Enterprise valuation
$28m (Public information from Sep 2024)
Share price
$1.026 PHGE
Ness Ziona Center District (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
EBITDA | (27.7m) | (33.9m) | (24.7m) | (23.1m) | (36.9m) | (43.3m) | (51.0m) |
Profit | (30.1m) | (36.2m) | (28.3m) | (26.2m) | (28.2m) | (35.1m) | (45.9m) |
EV / EBITDA | -5.3x | -1.3x | -0.2x | -0.6x | -0.6x | -0.5x | -0.4x |
R&D budget | 20.9m | 22.7m | 16.2m | 16.7m | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | €21.8m | Series A | |
N/A | Support Program | ||
* | $32.0m | Series B | |
N/A | N/A | IPO | |
* | $7.5m | Private Placement VC | |
* | $50.0m | Private Placement VC | |
Total Funding | $113m |
Recent News about BiomX
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by BiomX
EditACQUISITION by BiomX Mar 2024
ACQUISITION by BiomX Dec 2017